VistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent regarding Breakthrough Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders and Cancer Aug 8, 2017
VistaGen Therapeutics Appoints Dr. Mark Wallace to Clinical Advisory Board to Advance AV-101 as a Potential Non-Opioid Treatment for Neuropathic Pain Jul 10, 2017
VistaGen Therapeutics Reports Fiscal 2017 Financial Results and Provides Corporate Update Jun 29, 2017
VistaGen Announces Peer-Reviewed Publication in the Scandinavian Journal of Pain Highlighting Orally-Available AV-101's Excellent Safety Profile and Potential as a Non-Opioid Treatment for Neuropathic Pain Jun 22, 2017
VistaGen Therapeutics Announces Peer-Reviewed Publication in The Journal of Pain Highlighting AV-101's Potential for Treating Neuropathic Pain Apr 27, 2017
VistaGen Therapeutics Receives European Patent Office Notice of Intention to Grant European Patent for AV-101 Mar 29, 2017
VistaGen Therapeutics to Ring the Nasdaq Stock Market Closing Bell on Monday, March 13, 2017 Mar 8, 2017
VistaGen Therapeutics Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update Feb 13, 2017
